PPARG and malignant colon neoplasm: The decrease in CSC features under DM was likely reinforced by the presence of the PPARgamma ligand rosiglitazone, considering the role of PPARgamma in reducing tumorigenic features such as soft‐agar colony growth observed in overexpression studies performed in H2122 lung cancer [73], and colon cancer [74] models, so it would be of interest to test alternative analogues or ranges of concentrations.